Finnish researchers identify the cause for LGL leukemia

May 16, 2012

Researchers of the University of Helsinki, Helsinki University Central Hospital and Institute for Molecular Medicine Finland, have discovered that a mutation in the STAT3 gene is an underlying cause for LGL leukemia. Since the STAT3 gene is also abnormally expressed in many other cancers and autoimmune diseases, this finding has roused extensive interest. The research will be published in the New England Journal of Medicine on Thursday, May 17, 2012.

LGL leukemia is a relatively rare, malignant blood disease of the mature T-cells and, in many cases, it is related to such as rheumatoid arthritis. The pathogenetic mechanism of the disease has been unknown and it has previously been unclear if the disease is an overreaction of the normal defense system or a malignant hematological disease.

One of the key symptoms of LGL disease is a low count of (neutrophils), which may predispose the patients to life-threatening infections.

It was discovered that patients suffering from LGL leukemia have a mutation in the STAT3 gene in a very restricted SH2 area, which has a key effect on the function of the gene. This is not an inherited but a so-called acquired mutation. The cause for the mutation is not known, but probably or some other long-term antigen exposure can be predisposing factors. The STAT3 gene plays a key role in many .

After the finding, the prevalence of the mutation in LGL patients was verified using a larger patient group (77 patients) in cooperation with research groups at the Ohio (Prof. Maciejewski) and Pennsylvania (Prof. Loughran) Universities. It was discovered that 40% of all LGL patients present with the STAT3 mutation.

In the future, this result can be utilized in diagnosing the disease and possibly also in treatment, since the first STAT3 inhibitors are already undergoing early clinical trials. In addition, the research discovered that those LGL patients who had a mutation in the STAT3 gene were also more likely to suffer from rheumatoid arthritis. Hence, the research group intends to clarify next if patients suffering from rheumatoid arthritis can be found with similar gene mutations. If such mutations were to be found this would introduce new opportunities to the pathogenetic mechanisms of rheumatoid arthritis and other autoimmune diseases.

Explore further: Combination drug therapy urged to battle lung cancer

Related Stories

Combination drug therapy urged to battle lung cancer

February 2, 2012
Combination drug therapy may be needed to combat non-small cell lung cancer (NSCLC), according to a study by the Translational Genomics Research Institute (TGen) and Van Andel Research Institute (VARI).

Researchers find important 'target' playing role in tobacco-related lung cancers

February 9, 2012
Researchers at Moffitt Cancer Center in Tampa, Fla., have discovered that the immune response regulator IKBKE (serine/threonine kinase) plays two roles in tobacco-related non-small cell lung cancers. Tobacco carcinogens induce ...

New drug target for kidney disease discovered

April 26, 2011
Two discoveries at UC Santa Barbara point to potential new drug therapies for patients with kidney disease. The findings are published in this week's issue of the Proceedings of the National Academy of Sciences.

Recommended for you

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

Popular immunotherapy target turns out to have a surprising buddy

August 16, 2017
The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.